CAPE (Caffeic acid phenethyl ester)-based propolis extract (Bio 30) suppresses the growth of human neurofibromatosis (NF) tumor xenografts in mice

Phytotherapy Research

Volumn 23, Issue 2, 2009, Pages 226-230

  Demestre, M ^a   Messerli, S M ^b   Celli, N ^c   Shahhossini, M ^a   Kluwe, L ^a   Mautner, V ^a   Maruta, H ^a,d  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MARINE BIOLOGICAL LABORATORY   (United States)

^c Santa Maria Imbaro   (Italy)

^d NF Cure Japan   (Australia)

Author keywords

AIDS; Bio 30; CAPE; Fragile x syndrome; MM; Neurofibromatosis; NF1; NF2; Propolis

Indexed keywords

BIO 30; CAFFEIC ACID PHENETHYL ESTER; P21 ACTIVATED KINASE 1; PROPOLIS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAFFEIC ACID DERIVATIVE; DRUG DERIVATIVE; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; PHENETHYL ALCOHOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEURILEMOMA; NEUROFIBROMATOSIS; NONHUMAN; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG SCREENING; NUDE MOUSE; TUMOR CELL LINE;

APOIDEA; MUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CAFFEIC ACIDS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, NUDE; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; P21-ACTIVATED KINASES; PHENYLETHYL ALCOHOL; PROPOLIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 59449102431     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2594     Document Type: Article

References (19)

1. Celli N, Mariani B, Dragani LK et al. 2004. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of caffeic acid phenethyl ester in rat plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 810: 129-136.
2. Grunberger D, Banerjee R, Eisinger K et al. 1988. Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis. Experientia 44: 230-232.
3. Hayashi ML, Rao BS, Seo JS et al. 2007. Inhibition of p21- activated kinase rescues symptoms of fragile X syndrome in mice. Proc Natl Acad Sci USA 104: 11489-11494.
4. Hirokawa Y, Arnold M, Nakajima H et al. 2005a. Signal therapy of breast cancer xenograft in mice by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 4: 956-960.
5. Hirokawa Y, Nakajima H, Hanemann O et al. 2005b. Signal therapy of NF1-deficient tumor xenograft in mice. Cancer Biol Ther 4: 379-381.
6. Hirokawa Y, Nheu T, Grimm K et al. 2006. Sichuan pepper extracts block the PAK1/Cyclin D1 pathway and the growth of NF1- deficient cancer xenograft in mice. Cancer Biol Ther 5: 305-309.
7. Hirokawa Y, Tikoo A, Huynh J et al. 2004. A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor. Cancer J 10: 20-26.
8. Kiosses WB, Hood J, Yang S et al. 2002. A dominant-negative p65 PAK peptide inhibits angiogenesis. Circ Res 90: 697-702.
9. Lepont P, Stickney JT, Foster LA et al. 2008. Point mutation in the NF2 gene of HEI-193 human Schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity. Mutat Res 637: 142-151.
10. Maruta H, Ohta T. 2008. Signal therapy: propolis and pepper extracts as cancer therapeutics. In Complementary and Alternative Therapies and the Aging Population, Watson RR (ed.). Elsevier Inc: San Diego, in press.
11. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
12. Murray TJ, Yang X, Sherr DH. 2006. Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A. Breast Cancer Res 8: R17.
13. Nguyen DG, Wolff KC, Yin H et al. 2006. 'UnPAKing' human immunodeficiency virus (HIV) replication: using small interfering RNA screening to identify novel cofactors and elucidate the role of group I PAKs in HIV infection. J Virol 80: 130-137.
14. Porchia LM, Guerra M, Wang YC et al. 2007. 2-Amino-N-{4-[5- (2-phenanthrenyl)-3-(trifiuoromethyl)-1H-pyrazol-1-yl]-phenyl) acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 72: 1124-1131.
15. Prabhakar S, Messerli S, Stemmer-Rachamimov A et al. 2007. Treatment of implantable NF2 Schwannoma tumor models with oncolytic herpes simplex virus G47Delta. Cancer Gene Ther 14: 460-467.
16. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T et al. 2003. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett 195: 161-168.
17. Sforcin JM. 2007. Propolis and the immune system: a review. J Ethnopharmacol113: 1-14.
18. Xu JW, Ikeda K, Kobayakawa A et al. 2005. Down-regulation of Rac1 activation by caffeic acid in aortic smooth muscle cells. Life Sci 76: 2861-2872.
19. Zhang S, Suvannasankha A, Crean CD et al. 2007. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 13: 4750-4758.